Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Greatest Hits of 2024
CONFERENCE HUB
Start Learning
Should we intensify chemotherapy in the treatment of acute myeloid leukemia? Insights from ASH 2024
Madrid Skyline
JOURNALS
Start Learning
EHA2024 Hybrid Congress 13-16 June, Madrid
touchCONGRESS
Start Learning
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
CE/CME ACCREDITED
touchPANEL DISCUSSION
Start Learning
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
CE/CME ACCREDITED
touchSYMPOSIUM
Start Learning
Collaboration in chronic ITP: Improving quality of life and patient outcomes
CE/CME ACCREDITED
JOURNALS
Start Learning
Supporting haematology patient care: Insights from the Haematology Nurses and Healthcare Professionals Group
CONFERENCE HUB
Start Learning
DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia
Combination Therapy in Myelofibrosis: John Mascarenhas on the IMpactMF trial
CONFERENCE HUB
Start Learning
Navtemadlin in myelofibrosis: Advancing treatment with MDM2 inhibition
touchMDT
Start Learning
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making
View
ATRA + ATO vs SoC in high-risk APL: APOLLO trial
View
Durable clinical benefit with elritercept in lower-risk MDS: KER050-MD-201 trial
View
Multiple myeloma insights at EHA 2024
View
Supporting young haematologists: Insights on YoungEHA and EHA 24
View
Navtemadlin in myelofibrosis: Advancing treatment with MDM2 inhibition
View
Isatuximab demonstrated consistent PFS benefits across diverse patient profiles in RRMM in 2 pivotal trials
View
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
View
Should we intensify chemotherapy in the treatment of acute myeloid leukemia? Insights from ASH 2024
View
#ASH24: The countdown is on!
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup